TJC Management for behavioral Health MM 01.01.05

PLEASE NOTE:   Posts made to this forum should not be considered as the expressed opinions of, nor should be considered endorsed by, the Medication Safety Officer’s Society (MSOS) or the Institute for Safe Medication Practices (ISMP). 

Make sure your email is up-to-date
In order to continue to receive updates from MSOS, as well as forum posts and other valuable information as a member of MSOS, please be sure to update your email address with us, whenever it changes. If you need assistance doing so, please send an email to jrufo@ismp.org. 

1 post / 0 new
Log in or register to post comments
Wed, 11/09/2022 - 10:13
#1
Mohamed Sarg
Mohamed Sarg's picture
Offline
Last seen: 3 months 2 weeks ago
Joined: 01/16/2016 - 12:34
TJC Management for behavioral Health MM 01.01.05

Dear Collogues,

We just opened a behavioral Health institution and we are in the process of getting it accredited by TJC. Standard MM 01.01.05 requires the institution to have a dedicated policy to to address the following issues.
1. The use of multiple psychotropic agents in the same class
2. The use of high-dose pharmacotherapy
3. The prevention, identification and management of side effects, including tardive dyskinesia.

I was wondering if someone here oversee a behavioral health institution can share their policy that meet that standard to guide us when we are drafting our own.

Thanks in advance for all your help.
Mohamed

Top